Pre-chemotherapy MUC16 levels correlate strongly with patient outcomes and treatment responsiveness, with lower baseline values predictive of extended progression-free survival, suggesting the biomarker’s prognostic value in NSCLC management strategies (233). This evidence concerns the gene MUC16 and non-small cell lung carcinoma.